Physician profile
Matthew D Shulman
NPI 1730599903
$21,739.35
in general payments reported to CMS, 2019-2025
43 companies · $4,920 in 2025
The $4,920 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,383 · 2020: $884 · 2021: $2,334 · 2022: $3,511 · 2023: $3,845 · 2024: $4,864 · 2025: $4,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,998 · Consulting Fee: $3,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,997.93 |
| Consulting Fee | $3,630.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $3,282.01 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $1,909.97 | 2020-2025 | Simbrinza, Clareon, Tryptyr |
| Sun Pharmaceutical Industries INC. | $1,745.75 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $1,745.67 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $1,576.70 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $1,312.38 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Mallinckrodt Hospital Products INC. | $1,305.11 | 2020-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $906.18 | 2019-2022 | |
| Biotissue Holdings INC. | $854.15 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $826.63 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $813.49 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $555.82 | 2022-2025 | Eylea, Eylea Hd |
| Dompe US, INC. | $523.28 | 2022-2025 | Oxervate |
| Horizon Therapeutics Plc | $515.84 | 2019-2023 | Tepezza |
| Abbvie INC. | $485.98 | 2022-2025 | Durysta, Lumigan, Alphagan P |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $366.52 | 2024-2025 | Vevye, Tobradex St, Ilevro |
| Omeros Corporation | $366.30 | 2019-2021 | |
| Thea Pharma INC. | $312.37 | 2022-2025 | Iyuzeh |
| Allergan, INC. | $282.45 | 2021-2022 | |
| Astellas Pharma US INC | $231.32 | 2024-2025 | Izervay |
| Eyevance Pharmaceuticals LLC | $187.14 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $180.05 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $174.72 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $166.28 | 2022-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Apellis Pharmaceuticals, INC. | $152.35 | 2022-2024 | Syfovre |
| Amgen INC. | $139.81 | 2024-2025 | Tepezza |
| Merz Pharmaceuticals, LLC | $133.18 | 2021-2025 | Xeomin |
| Genentech USA, INC. | $109.71 | 2023-2025 | Vabysmo |
| Mallinckrodt Enterprises LLC | $104.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $79.14 | 2023-2024 | Purified Cortrophin Gel |
| Rxsight INC | $62.03 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Glaukos Corporation | $47.94 | 2025 | Idosetr |
| Coherus Oncology, INC. | $43.64 | 2023 | |
| Alimera Sciences, INC. | $35.57 | 2022 | |
| Eyepoint US, INC. | $33.03 | 2022 | |
| Immunocore Limited | $30.33 | 2023 | Kimmtrak |
| Shire North American Group INC | $28.64 | 2019 | |
| Dutch Ophthalmic, USA | $26.45 | 2022 | |
| Akorn, INC. | $19.46 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Kedrion Biopharma, INC. | $16.94 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Lensar, INC. | $16.62 | 2020 | |
| Quidel Corporation | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.